To confirm the relevance of MBNL loss of function in cardiac dysfunctions in DM1, we developed a real-time fluorescence polarization/anisotropy assay to identify pharmacological compounds reducing MBNL1 binding to pathogenic CUG repeats. This evidence concerns the gene MBNL1 and myotonic dystrophy type 1.